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THE EFFECTS OF TROGLITAZONE AND PMA ON AMPK IN HEPG2 CELLS 
KATHERINE M. ALLEN 
ABSTRACT 
 Type 2 diabetes, as well as other metabolic diseases, is an increasing global health 
concern and many of the mechanisms of both the disease and its current drug treatments 
have not been fully described. It has been shown that the anti-diabetic class of drugs, the 
thiazolidinediones, work via both a known PPARγ-dependent, and a lesser known 
PPARγ-independent mechanism of action. This PPARγ-independent mechanism likely 
involves the metabolic regulatory molecule AMPK, which has a newly elucidated 
inhibitory site of phosphorylation at Ser
485/Ser491
. In this study we sought to determine if 
the thiazolidinedione troglitazone affects AMPK in HepG2 liver cells via 
phosphorylation at both the known Thr
172
 site as well as the letter understood Ser
485
 site. 
We also looked for potential upstream kinases of the Ser
485
 site by comparing our results 
to recently proposed mechanisms of phosphorylation here. 
 HepG2 cells were cultured in the lab and treated with troglitazone to determine 
time- and dose- dependent effects on AMPK. We also treated cultured HepG2 cells with 
PMA as well as troglitazone and PMA in order to compare mechanisms of action of 
troglitazone on AMPK. Results were analyzed using common western blot techniques 
and statistical analysis. 
 Our data found that troglitazone increased AMPK activity by increasing 
phosphorylation at Thr
172
 in a time- and dose- dependent manner. The inhibitory site 
Ser
485
 was also increasingly phosphorylated with troglitazone treatments, although the net 
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result of troglitazone treatment remained AMPK activation. The recently elucidated 
results from our laboratory showing the mechanism of p-AMPK Ser
485
 phosphorylation 
via PKD after PMA treatment also occurred in HepG2 cells, although this did not appear 
to be the mechanism by which troglitazone phosphorylated AMPK at Ser
485
. 
 These data support the current research that there is an AMPK mediated PPARγ-
independent mechanism of troglitazone treatment for type 2 diabetes and other metabolic 
diseases. The results do however bring into question the full effects of the drug on AMPK 
at a molecular level and leaves room for new research in this area, specifically the exact 
mechanism by which troglitazone phosphorylates AMPK at Ser
485
. Our data also brings 
up new questions as to the simultaneous phosphorylation of AMPK at both Thr
172
 and 
Ser
485
 and what this means for the activity of the molecule as a whole, a current area of 
critical research. Lastly our data support the newly elucidated mechanism of AMPK 
phosphorylation at Ser
485
 via PKD1, an exciting and novel discovery and potential target 
for therapeutic intervention. 
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INTRODUCTION 
Diabetes: A Global Health Crisis 
It is well known that type 2 diabetes (T2D), as well as other metabolic diseases 
such as obesity and metabolic syndrome, are becoming increasingly common afflictions. 
According to the American Diabetes Association, the incidence of diabetes in the United 
States is projected to rise to 29 million in 2050, an increase of 165% from the year 2000 
(Boyle et al., 2001). Worldwide, the current estimate of over 250 million people suffering 
from T2D is projected to increase to 366 million by the year 2030 and will be the 7
th
 
leading cause of death (Wild et al., 2004). In addition to the diabetes itself, patients 
suffering from the disease also have an increased risk of hypertension, heart attack, 
stroke, kidney disease, blindness, and amputations to name just a few (Centers for 
Disease Control and Prevention, 2014). Aside from the human impact, T2D is an 
expensive problem. In 2012 the estimated cost of diabetes in the United States alone was 
$245 billion, and this is projected to rise along with the incidence of the disease itself, 
putting added strain onto already heavily burdened economies (American Diabetes 
Association, 2013). In light of these alarming statistics it is clear that attaining a greater 
understanding the diabetes disease process will be crucial in helping with the health of 
the global population in the years to come. 
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Type 2 Diabetes 
Type 2 diabetes is an extremely complex disease that involves a vast number of 
interconnected molecular pathways that affect multiple body systems. Accordingly, a 
great amount of research is still needed in order to both fully elucidate the mechanisms of 
the disease and to create the most effective treatments and medications. Although the 
process is not fully understood, it is known that T2D is caused by a mixture of both 
genetic and environmental factors (Alsahli and Gerich, 2012). Many gene mutations have 
been identified that put people at a higher risk for developing T2D, yet these have not 
been conclusively linked to a specific type of diabetes not have their exact physiological 
effects been identified (Alsahli and Gerich, 2012). The environmental factors that place 
an individual at risk for developing T2D are relatively better known, with high BMI, 
unhealthy diet, and lack of physical activity being the three main culprits (Alsahli and 
Gerich, 2012).  
These hereditary and environmental factors work together to cause T2D is via 
their effects on the way the body produces and uses insulin (Codario, 2011). Sufferers 
may express varying levels of increased insulin resistance in tissues throughout the body, 
impaired insulin secretion (from pancreatic β cells), and/or increased hepatic 
gluconeogenesis and glucogenolysis (Codario, 2011). Specifically, it is thought that 
insulin resistance leads to increased glucose production from the liver, decreased 
systemic glucose uptake, and increased lipolysis (Marks, 2012). The increased lipolysis 
leads to increased levels of circulating free fatty acids (FFA) which in turn stimulate 
gluconeogenesis in the liver and further hepatic glucose output (Marks, 2012).  
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Current treatments for T2D focus on both lifestyle improvements and medications. The 
current medications on the market work to increase/normalize insulin levels and/or target 
many of the other underlying mechanisms of the disease (Marks 2012). It is these non-
insulin anti-diabetic agents that this study will focus on, specifically a class of drugs 
called thiazolidinediones that are thought to improve insulin sensitivity and therefore 
increase glucose uptake and utilization (Kahn et al., 2000). 
 
AMPK 
AMP-activated protein kinase (AMPK) is a molecule found in almost every cell 
in the human body. The molecule is a serine/threonine kinase consisting of three 
subunits, a catalytic α-subunit and regulatory β- and γ-subunits, each of which has 
multiple isoforms (O’Neill, 2013). Different isoforms tend to be found in different 
tissues, the most common example of which is α1-containing isoforms which are most 
predominant in the liver and adipose tissue, and α2-containing isoforms which are most 
predominant in skeletal muscle, brain, and heart (Steinberg and Kemp, 2009). AMPK’s 
primary purpose is regulation of cellular metabolic functions including, but not limited to, 
glucose and lipid homeostasis, adipokine driven regulation of food intake, and body 
weight (Kahn et al., 2005). When activated, AMPK phosphorylates many downstream 
targets that lead to the inhibition of pathways that consume energy, such as fatty acid 
synthesis, cholesterol synthesis, and gluconeogenesis (Saha et al., 2014). This 
downstream phosphorylation also leads to the stimulation of pathways that generate 
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energy, glucose uptake, fatty acid oxidation, glycolysis, and food intake to name a few 
(Saha et al., 2014). 
 
AMPK Regulation 
In order for AMPK to be activated it is necessary to have both an increase in 
intracellular AMP:ATP ratio and phosphorylation of Thr
172
 on the α-subunit of the 
molecule (Kahn et al., 2005). The increase in AMP molecules (and potentially ADP 
molecules) that occur as a result of low cellular energy bind to the γ subunit of the 
AMPK, causing an allosteric change that allows upstream kinases to phosphorylate the 
molecule at the Thr
172
 site on the α subunit (Fullerton, 2016). It should also be noted that 
this conformation change makes it more difficult for dephosphorylation by protein 
phosphatases (Fullerton, 2016). There are currently three known kinases that 
phosphorylate AMPK at the Thr
172
 location; liver kinase B1 (LKB1), a tumor suppressor 
(Kahn et al., 2005), the calcium/calmodulin-dependent protein kinase β (CaMKKβ) 
(Hawley et al., 2005), and transforming growth factor-β activated protein kinase-1 
(TAK1) (Momcilovic et al., 2006). Aside from these three kinases, there are a vast 
number of known, upstream AMPK activators of physiological, hormonal, natural, and 
pharmacological origin (Saha et al., 2014). Physiological activators of AMPK are thought 
to be exercise and calorie restriction as they help increase the cellular ratio of AMP:ATP 
(Richter and Ruderman, 2009). Resveratrol, a polyphenol found in red wine, rooibos, a 
South American plant, berberine, an alkaloid found in certain plants, and α-lipoic acid, a 
short-chain fatty acid, are just a few of the naturally occurring compounds thought to 
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activate AMPK as well as the hormones leptin, adiponectin, and interleukin-6 (IL-6) 
(Saha et al., 2014). Pharmacological activators of AMPK include 5-Aminoimidazole-4-
carboxamide riboside (AICAR) (Sullivan et al., 1994), biguanides such as Metformin 
(Nathan et al., 2009), and most importantly for the purposes if this study, the 
thiazolidinediones which include troglitazone, rosiglitazone, and pioglitazone 
(LeBrasseur et al., 2006).  
 Much less is known about factors that inhibit AMPK relative to the vast wealth of 
information regarding its activation. Two sites that have been shown to inhibit AMPK 
activation are found at Ser
485
 of the α1 subunit and Ser491 of the α2 subunit (Horman et 
al., 2006). As summarized by Coughlan et al., in 2014, the current known mechanisms of 
phosphorylation here are through auto-phosphorylation and by the molecules Akt 
(primarily at Ser
485
), protein kinase A (PKA), p70S6K (primarily at Ser
491
), and protein 
kinase Cµ/protein kinase D1 (PKCμ/PKD1) (Coughlan et al., 2016). This 
phosphorylation has been demonstrated in many tissues throughout the body including 
the heart, hypothalamus, adipocytes, smooth muscle cells, HEK293 cells (human 
embryonic kidney cells), and HepG2 cells (cultured human hepatocytes) (Saha et al., 
2014) (Coughlan et al., 2016). Interestingly, there is not yet a conclusive link between 
phosphorylation at Thr
172
 and Ser
485/491
, with some studies showing a reciprocal change in 
phosphorylation (Horman et al., 2006), and others demonstrating no significant Thr
172
 
changes with changes in Ser
485/491 
(Coughlan et al., 2016). In an even broader sense, there 
is still a great amount of debate over the both the natural and dysfunctional conditions 
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that lead to Ser
485/491 
phosphorylation, however both our own and other recent studies 
have found that it may be implicated in T2D as described below. 
 
 
 
Figure 1: General mechanism of AMPK activation vs. lesser known mechanism of 
AMPK inhibition. 
It is well known that both a rise in the AMP:ATP ratio along with phosphorylation at 
AMPK Thr
172
 increases AMPK activity. A lesser known mechanism of regulation 
involves phosphorylation of AMPK at Ser
485/491 
which leads to decreased AMPK activity. 
Cellular conditions caused by excess nutrients, such as high insulin and high glucose 
(common in type 2 diabetes) have been shown to increase both Akt and PKD which 
directly phosphorylate AMPK at Ser
485/491 
(Valentine et al., 2014) (Coughlan et al., 
2016). Adapted from Viollet et al. Targeting the AMPK pathway for the treatment of 
Type 2 diabetes. Frontiers in Bioscience. 2009 
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AMPK Dysfunction in Type 2 Diabetes 
Because AMPK plays such an important role in cellular metabolism it is a logical 
target of investigation when trying to understand the molecular mechanisms underlying 
insulin resistance and type 2 diabetes, as well as other metabolic diseases. As discussed 
previously, it is known that prolonged exposure of normally insulin sensitive tissues 
(especially liver, skeletal muscle, and fat) to high levels of glucose, insulin, and FFAs can 
lead to the pathological changes seen in T2D (Coughlan et al., 2013). 
Recent studies aimed at understanding such changes have pinpointed AMPK, 
specifically its decreased activity, as a major factor in the aforementioned disease 
processes (Coughlan et al., 2016). On the most basic level, a number of animal model 
studies have shown that having the phenotype for metabolic syndrome is correlated with 
decreased AMPK activity in skeletal muscle (Ruderman and Prentki, 2004). In humans, it 
is known that AMPK inhibition is an early onset event in the process of developing 
insulin resistance, an important point when discussing early intervention therapies 
(Kraegen et al., 2006). Supporting this fact, studies have found that patients suffering 
from obesity or T2D have consistently decreased AMPK activity in skeletal muscle and 
adipose tissue (Bandyopadhyay et al., 2006) (Xu et al., 2012). More recent studies have 
shown that it is the acute insulin resistance present in T2D that is directly correlated with 
impaired skeletal muscle AMPK activity (Lee-Young et al., 2013). 
On a molecular level, our lab and others have demonstrated that both rat extensor 
digitorum longus (EDL) muscle and MIN6 pancreatic beta cells, when incubated with 
high glucose, show decreased phosphorylation of AMPK at Thr
172
 as well as increased 
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phosphorylation of α1 AMPK at Ser485 (Garcia-Har et al., 2012) (Coughlan et al., 2015). 
We recently sought to discover some of the potential upstream kinases causing the 
changes in AMPK regulation by incubation skeletal muscle cells in the diacylglycerol 
(DAG) mimetic phorbol 12-myristate 13-acetate (PMA). DAG is increased in states of 
high glucose exposure and has previously been shown to decrease AMPK activity 
(Coughlan et al., 2016). We discovered that the decrease in AMPK activity was caused 
by an increase in Ser
485/491 
phosphorylation via protein kinase D (PKD) as well as the 
previously elucidated molecule Akt (Coughlan et al., 2016). In liver in particular, it was 
recently shown that a simple high fat diet leads to early increases in Akt activity which in 
turn leads to decreased p-AMPK Thr
172
 and overall decreased AMPK activity (Shiwa et 
al., 2015). Our lab showed similar results in liver cells treated with insulin, showing 
increased Akt activity leading to decreased AMPK activity, however these results 
demonstrated an increase in p-AMPK Ser
485
 and no significant change in p-AMPK Thr
172
 
(Valentine et al., 2014). It should be noted that the same results were also found with 
insulin treatments of C2C12 muscle cells and intact rat EDL muscle (Valentine et al., 
2014). 
Because of this clear link between T2D, and other metabolic diseases, and AMPK 
dysfunction it is evident that it is a promising potential target for further research as well 
as therapeutic intervention. More investigation into these mechanisms will also help us 
gain a better understanding of the mechanisms involved. Despite this evidence however, 
there are currently no available drugs for T2D or any other metabolic disease that directly 
target AMPK, although an increasing body of research is finding that current drugs do 
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impact this molecule in not yet fully understood ways (Saha et al., 2014). One class of 
drugs currently used for treatment of T2D that have been shown to have some effect on 
AMPK are the thiazolidinediones (TZDs). 
 
Thiazolidinediones (TZDs) 
As described previously, TZDs are a class of antidiabetic drugs including 
troglitazone, rosiglitazone, and pioglitazone, which have been shown to reduce plasma 
and insulin levels as well as improve lipid metabolism in insulin resistant animal models 
(Kahn et al., 2000). Clinical trials have shown that diabetic patients treated with TZDs 
show lowered serum glucose and insulin levels, decreased triglyceride levels, and other 
positive changes regarding their general metabolic state (Saltiel and Olefsky, 1996). It 
was initially posited that TZDs work primarily as ligands for the peroxisome proliferator 
activated receptor γ (PPARγ), a receptor expressed primarily in adipocytes (Kahn et al., 
2000). Although the normal function of PPARγ is not clear, TZD binding to PPARγ has 
been shown to improve insulin-resistance in both humans and animals by an unknown 
mechanism (Kahn et al., 2000). Despite the relatively strong evidence, subsequent studies 
trying to gain a more in-depth understanding of the drugs’ action have shown that the 
PPARγ-mediated mechanism does not account for all the effects of TZDs. Several studies 
have shown not only that the effects of TZDs can be seen on a timescale that would rule 
out PPARγ-mediated alterations of gene expressions, but also that TZDs exhibit a 
considerable effect on many cells other than adipocytes (LeBrasseur et al., 2006). 
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Although it has been shown that alternate mechanisms of action must exist, these 
mechanisms have yet to be fully described. 
 It was first theorized that direct AMPK may be implicated in TZDs’ antidiabetic 
effects when a study showed that TZDs (along with another antidiabetic drug, 
Metformin) strongly activated the AMPK pathway, leading to beneficial downstream 
metabolic effects (Schimmack et al., 2006). Furthermore another study found evidence 
showing that not only do TZDs directly affect AMPK activity, but also that the 
abundance of PPARγ has no correlation with noted AMPK change (LeBrasseur et al., 
2006).  
On a molecular level it has been shown that the TZD troglitazone increases 
phosphorylation of AMPK at Thr
172
 in rat EDL muscle, indicating activation of the 
enzyme (LeBrasseur et al., 2006). Our lab has previously demonstrated that the TZD 
pioglitazone increases phosphorylation of AMPK at Thr
172
 in both normal and 
hyperinsulinemic rat livers (Saha et al., 2004). As a potential alternative mechanism, 
some of the aforementioned studies found an increase in skeletal muscle AMPK activity 
after troglitazone treatment has been associated with an increased AMP:ATP ratio 
(LeBrasseur et al., 2006). As mentioned before, an increased AMP:ATP ratio is one of 
the basic conditions needed for AMPK activation. This link between TZD treatment and 
an increased AMP:ATP ratio potentially supports two other proposed mechanisms of 
TZD action, that 1) TZDs bind to and inhibit mitochondrial proteins that may inhibit ATP 
production, and 2) TZDs somehow reduce mitochondrial membrane potential in turn 
affecting the ATP levels of the cell (Brunmair et al., 2004). 
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 Despite this suspected PPARγ-independent correlation between TZD treatment 
and p-AMPK Thr
172
 increase, the complete mechanism of action has not been fully 
elucidated. Furthermore, there has been little, if any, research on changes in p-AMPK 
Ser
485/491 
phosphorylation, a potential new target for regulating AMPK activity. 
 
 
 
Figure 2: Medications used to treat type 2 diabetes and their generally proposed 
targets of action. 
Many different drugs are prescribed in order to decrease the high glucose levels 
associated with T2D. Highlighted here in red are the organs that TZDs are thought to 
target and their general mechanism of action. Adapted from (Marks, 2012). 
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Summary 
The increasing health crisis that is type 2 diabetes forces us to increase our depth 
of understanding of the mechanisms of both T2D and its current and potential treatments. 
The molecule AMPK is continually implicated in T2D, and the recently elucidated 
method of inhibition of AMPK, phosphorylation at Ser
485/491
, provides a new lens through 
which to study this disease. In addition to understanding the disease processes, 
discovering the mechanisms that known therapeutic treatments, such as the 
thiazolidinediones, have on AMPK activity (in particular the lesser known Ser
485/491
) will 
both elucidate the current mechanisms of action of medications as well as provide new 
potential points of therapeutic intervention. 
 The aim of this study is to understand the effects of the thiazolidinedione 
troglitazone on AMPK in HepG2 cells. We hope to determine the effects on not only the 
well-studied Thr
172
 activation site, but also the Ser
485
 inhibition site. After determining 
troglitazone’s effect on AMPK, we hope to elucidate potential upstream kinases that may 
be causing these effects and by doing so we hope to provide some insight into the 
mechanisms of action that troglitazone has, particularly on Ser
485
 of AMPK. 
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Specific Aims 
The specific aims of this thesis are: 
1. To assess the effects of troglitazone on AMPK in HepG2 cells. 
HepG2 cells will be incubated at a number of different time points and at a variety of 
different concentrations of troglitazone. After incubation we will measure the amount of 
protein phosphorylated at both Thr
172
 and Ser
485
 to see if or how they changed with 
incubation. We will also measure the phosphorylation of ACC which is directly 
phosphorylated by AMPK and is a good indication of its activity. These data will be 
analyzed by western blotting. We hope to discover what effect troglitazone has on AMPK 
phosphorylation at both Thr
172
 and Ser
485
. We also hope to find the maximum time point 
and dose at which these effects occur. 
 
2. To determine if troglitazone or PMA treatments lead to phosphorylation of AMPK 
at Ser
458
 in HepG2 cells by PKD. 
HepG2 cells will be incubated with troglitazone, PMA, or both after which they will be 
tested for changes in phosphorylation of AMPK at Ser
458
 and of PKD at Ser
916
. 
Phosphorylation of AMPK at Thr
172
 will checked for comparison, and measurements of 
phosphorylation of pACC at Ser
79
 will be used to determine the effects of the treatments 
on the activity level of AMPK. All data will be collected via western blotting and 
analyzed for statistical significance. We will do this by measuring a variety of molecules 
previously found to affect phosphorylation of AMPK at Thr
172
 and Ser
485
. We hope to 
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first assess whether the same mechanism of AMPK Ser
491
 phosphorylation by PKD 
occurs in HepG2 cells, and to determine whether this mechanism is partially responsible 
for troglitazone’s effect on AMPK in HepG2 cells. 
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METHODS 
 
Cell Culture 
 HepG2 cells purchased from ATCC (Manassas, VA) were cultured in normal 
glucose (5.5 mM) Dulbecco’s Modified Eagle Medium (DMEM), with 1% 
penicillin/streptomycin (P/S), and 10% fetal bovine serum (FBS) purchase from 
Invitrogen (Grand Island, NY). They were kept in an incubator at 37°C, 5% CO2. Media 
was changed every 2 to 3 days and cells were passaged once they reached approximately 
80% confluence. 10 cm culture dishes were used for cell culture, and either 6- or 12-well 
plates were used for cell treatments. Cells were discarded after a maximum of 20 
passages. 
 
Cell Treatments 
 Prior to experimental treatments, HepG2 cells were serum starved in DMEM with 
1% P/S for a minimum of three hours. For dose-response experiments, troglitazone, 
purchased from Tocris Biosciences (Bristol, UK), was added directly to wells in differing 
amounts to make dilutions between 10 µM and 100 µM and then placed back into the 
incubator at 37°C, 5% CO2 for one hour prior to harvesting. For time-course experiments, 
troglitazone was added to wells for a concentration of 50 µM and incubated at 37°C, 5% 
CO2 from 5 minutes to 12 hours before harvesting. For experiments involving phorbol 
12-myristate 12-acetate (PMA) treatments, PMA was added to wells for a concentration 
of 50 nm and cells were incubated as mentioned above for 30 minutes. For experiments 
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involving PMA and troglitazone treatments, 50 µM troglitazone was first added to wells 
and incubated for a varying amount of time after which 50 nm PMA was added and cells 
were incubated for another 30 minutes then harvested. 
 
Cell Harvest 
 Upon completion of cell culture experiments, cell placed on ice and all media was 
aspirated. A lysis buffer containing 20 mM Tris-HCl - pH 7.5, 150mM NaCl, 1mM 
Na2EDTA, 1% triton, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM 
Na3VO4, 1µg/ml leupeptin was supplemented with a phosphate inhibitor cocktail (Sigma) 
and a protease inhibitor cocktail (Thermo Fisher Scientific) was applied to the wells. 
Cells were removed from wells using cell scrapers and placed into microcentrifuge tubes 
after which they were immediately centrifuged at 13,200 g for 10 minutes at 4°C and 
supernatant was removed. Protein concentration was assessed by the bicinchoninic acid 
method (BCA; Pierce Biotechnology, Inc., Rockford, IL). Samples were stored at -80°C 
until western blot analysis was ready to be performed. 
 
Western Blot Analysis 
 SDS-PAGE gel electrophoresis and immunoblotting were used in order to analyze 
the protein and phosphorylation expression of the experimental data. Samples were 
prepared based on BCA assay results to create an equal concentration, Laemmli Sample 
Buffer (Bio-Rad) and 0.5mM DTT were added and then samples were brought to equal 
volume with double distilled water. After heating at 90°C for 10 minutes, cooling on ice 
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for 10 minutes, and 1 minute of centrifugation at 13,200 g, samples were run on 12-, 18-, 
or 26-well Criterion TGX Precast gels. Transfer was either 3 hours or overnight onto a 
polyvinylidene difluoride membrane after which membranes were blocked in Tris-
buffered saline (pH 7.5) with 0.05% Tween-20 (TBST) and 5% non-fat dry milk for 1h 
while rocking. Most primary antibodies were diluted 1:1,000, actin was diluted 1:10,000, 
and incubated at 4°C overnight on a rocker. Primary antibodies for total AMPK, 
phospho-AMPKα (Thr172), phospho-AMPKα1 (Ser485), total Acetyl-CoA carboxylase 
(ACC), phospho-PKD (Ser
916
), total PKD, phosphor-PKC substrate, phospho-Akt, and 
total Akt were purchased from Cell Signaling Technology (Danvers, MA). Phospho-ACC 
(Ser
79
) was purchased from Upstate/Millipore (Temecula, CA). Anti-β-actin was 
purchased from Sigma-Aldrich (St. Louis, MO).The next day, membranes were washed 
and incubated with secondary antibodies at a 1:5,000 dilution for 1 hour at room 
temperature. Membranes were developed using enhanced chemiluminescence solution 
(ECL) (Pierce Biotechnology, Inc., Rockford, IL) onto autoradiography films.  
 
Statistical Analysis 
 Densitometry was performed using Scion Image software. Results were given as 
means ± S.E.M. Statistical significance was determined by 1 way ANOVA or by two-
tailed unpaired Student’s t tests with Bonferroni’s multiple comparison post-test.  
Statistical significance was considered a level of p < 0.05. 
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Table 1. List of antibodies used in western blotting. Each antibody used in western 
blot analysis with the dilution used, animal source, molecular weight at which the 
antibody is likely to be found, the temperature and time of incubation (O/N = overnight), 
and the supplier from which the antibody was purchased. Table modified from Kimberly 
Coughlan – dissertation. 
Antibody Dilution Source 
Predicted 
Molecular 
Weight Incubation Supplier 
Phospho-
AMPKα1 
(Ser485) 1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 
Phospho-
AMPKα 
(Thr172) 1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 
AMPKα 1:1000 Rabbit 62 kDa 4°C O/N 
Cell 
Signaling 
Phospho-
ACC 
(Ser79) 1:1000 Rabbit 280 kDa 4°C O/N 
EMD 
Millipore 
ACC 1:1000 Rabbit 280 kDa 4°C O/N 
Cell 
Signaling 
Phospho-
PKD/PKCμ 
(Ser916) 1:1000 Rabbit 115 kDa 4°C O/N 
Cell 
Signaling 
β-actin 1:10,000 Mouse 42 kDa 4°C O/N 
Sigma 
Aldrich 
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RESULTS 
 
Incubation of HepG2 cells with 50µM troglitazone increases phosphorylation of AMPK 
at Thr
172
, Ser
485
, and ACC at Ser
79
 over time. 
 It has been demonstrated that thiazolidinediones stimulate AMPK activation in 
many different cell types by increasing phosphorylation at Thr
172
 (LeBrasseur et al., 
2006). Our initial goals were to determine if these results were replicable with the TZD 
troglitazone in HepG2 cells (cultured liver hepatocytes), and if so over what time course 
they occurred. We incubated HepG2 cells with 50μL of troglitazone and collected the 
cells over two different time-courses; 5, 15, 30, 45, and 60 minutes for the acute time-
course and 0.5, 1, 2, 4, 6, and 12 hours for the extended time-course (Figures 3 and 4). 
Overall, phosphorylation of AMPK at Thr
172
 increased over time (Figures 3B and 4B). A 
trend can be noted beginning as early as 5 minutes where we found a 2-fold increase 
compared to the control during the acute time course (Figure 3B). The increase in 
phosphorylation was statistically significant (p <0.05) after one hour of incubation with 
levels of phosphorylation approximately 7-fold higher than the control (Figure 3B). 
Phosphorylation of Thr
172
 showed an increasing trend until it plateaued at 6 hours, 
remaining essentially the same for up 12 hours incubation at which time the increase was 
approximately 15-fold compared to the control (Figure 4B). Over the extended time 
course, phosphorylation of Thr
172
 was seen as early as 0.5 hours (the earliest time-point), 
however as with the acute time-course this increase was not considered statistically 
significant (p <0.05) (Figure 4B).  
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 We also sought to determine if troglitazone treatments had any effect on 
phosphorylation of the inhibitory site on AMPK at Ser
485
 in HepG2 cells and, if so, over 
what time period. We used the same two experiments mentioned above, an acute and an 
extended time-course (Figures 3 and 4). Our results showed a trending increase of 
phosphorylation beginning at just 5 minutes on an acute time scale with a statistically 
significant (p <0.05) 3.5-fold increase after one hour of incubation (Figure 4C). This 
increase, although significant, was approximately half the increase seen over one hour at 
Thr
172
 (Figure 3B). Phosphorylation of Ser
485
 continued to increase up with to 2 hours of 
incubation where it reached a 13-fold increase compared to the control (Figure 4C). After 
2 hours of incubation, a trend of decreasing Ser
485
 phosphorylation can be seen until at 
the 12-hour time point there is no significant difference (p <0.05) when compared to 
control (Figure 4C). Despite not being statistically significant, there is still well over a 5-
fold increase in phosphorylation of Ser
485
 after 12 hours and the increase is comparable to 
that seen after 0.5 hours of incubation (Figure 4C). As with the acute time-course, the 
increase in Ser
485 
phosphorylation over the extended time-course is less than the increase 
in Thr
172
 phosphorylation at each time point (Figures 3C and 4C). 
 Our final time based goal was to determine whether acetyl-CoA carboxylase 
(ACC), an enzyme directly phosphorylated at Ser
79
 by activated AMPK, was affected by 
troglitazone incubation of HepG2 cells. We used the same acute and extended time-
courses as mentioned before. Phosphorylation of ACC showed an increasing trend with 
over a 5-fold increase after only 5 minutes and a statistically significantly (p <0.05) 
increase after only 15 minutes of incubation (Figure 3D). Over the extended time-course, 
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the increase in phosphorylated ACC began to plateau after 1 hour of troglitazone 
incubation and stayed at an approximately 15-fold increase when compared to the control 
for up to 6 hours of troglitazone incubation (Figure 4D). However, by 12 hours of 
incubation there was a noticeable decrease in phosphorylation to similar levels seen at 0.5 
hours of troglitazone incubation (Figure 4D). This was a similar trend to that of p-AMPK 
Ser
485
, and, in the same way, there was still over a 5-fold increase when compared to 
control (Figures 4C and 4D). 
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Figure 3. Troglitazone treatment leads to an acute, time-dependent increase in 
phosphorylation at AMPK at Thr
172
 and Ser
485
 and of ACC at Ser
92
 in HepG2 cells. 
HepG2 cells were treated with 50μM of troglitazone and incubated for 5, 15, 30, and 60 
minutes. Western blot analysis was used to determine changes in p-AMPK Thr
172
, p-
AMPK Ser
485
, and p-ACC Ser
79
 (panel A). Panels B, C, and D are the quantification of 
the data obtained from panel A. Data are means ± SEM. N = 6 samples per group. *P < 
0.05 compared to control group. 
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Figure 4. Troglitazone treatment leads to an extended, time-dependent increase of 
phosphorylation at AMPK at Thr
172
 and Ser
485
 and of ACC at Ser
92
 in HepG2 cells. 
HepG2 cells were treated with 50μM of troglitazone and incubated for 0.5, 1, 2, 4, 6, and 
12 hours. Western blot analysis was used to determine changes in p-AMPK Thr
172
, p-
AMPK Ser
485
, and p-ACC Ser
79
 (panel A). Panels B, C, and D are the quantification of 
the data obtained from panel A. Data are means ± SEM. N = 4 samples per group. *P < 
0.05 compared to control group. 
  
 24 
Incubation of HepG2 cells with increasing doses of troglitazone corresponds to increased 
phosphorylation of AMPK at Thr
172
and Ser
485
, and of ACC at Ser
79
. 
 We next sought to determine the effects of different concentrations of troglitazone 
treatments on AMPK and ACC phosphorylation of HepG2 cells. To determine if there 
was any difference in concentration, we incubated HepG2 cells for one hour using 10, 25, 
50, and 100mM of troglitazone. 
 We found that there was an approximately 4-fold increase, in Thr
172
 
phosphorylation with 10µM and 25µM of troglitazone, however there was only a 
statistically significant (p <0.05) increase with 50µM and 100µM of troglitazone 
(approximately 14- and 17- fold increases compared to control respectively) (Figure 5B). 
The greatest increase in Thr
172
 phosphorylation was seen between 25µM and 50µM 
treatments (Figure 5B). Our results also show that, when incubated for 1 hour, it takes a 
concentration of at least 50μM to achieve a statistically significant increase in 
phosphorylation at AMPK Ser
485
; however an upward trend can be seen after treatment 
with 10μM of the troglitazone (Figure 5C). Similarly to Thr172, the greatest increase in 
Ser
485
 phosphorylation was seen between 25 and 50mM treatments (Figure 5C). Our last 
test within this experiment found that an increase in phosphorylation of ACC at Ser
79
 is 
already significant and almost 10 fold higher than the control at 25μM concentration. By 
50μM concentration there is a vast increase in phosphorylation, however there is little 
difference when doubling this dose to 100μM (Figure 5D). The same trend in ACC 
phosphorylation can be seen that was previously noted in both AMPK Thr
172 
and Ser
485
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phosphorylation – notably that the greatest increase in phosphorylation occurs between 
25mM and 50mM concentrations of troglitazone (Figure 5D). 
 
 
Figure 5. Troglitazone treatment leads to dose-dependent increase of 
phosphorylation at AMPK at Thr
172
 and Ser
485
 and of ACC at Ser
92
 in HepG2 cells. 
HepG2 cells were treated with 10, 25, 50, and 100μM of troglitazone and incubated for 1 
hour. Western blot analysis was used to determine changes in p-AMPK Thr
172
, p-AMPK 
Ser
485
, and p-ACC Ser
79
 (panel A). Panels B, C, and D are the quantification of the data 
obtained from panel A. Data are means ± SEM. N = 3 samples per group. *P < 0.05 
compared to control group. 
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HepG2 cells treated with PMA show increased phosphorylation of PKD1at Ser
916
and of 
AMPK at Ser
485
 and decreased phosphorylation of (AMPK at Thr
172
 and) pACC. 
We have previously shown that PKD1 is an upstream kinase of AMPK Ser
485
 in 
skeletal muscle that has been treated with PMA (Coughlan et al., 2016). In this study we 
found that in HepG2 cells treated with 50nM PMA for 30 minutes there is over a 15-fold 
increase in phosphorylation of PKD at Ser
916
 (Figure 6B). In addition, we observed an 
almost 7-fold increase in phosphorylation of AMPK at Ser
485
 with incubation of PMA 
(Figure 6C). Although there is no evidence in the literature of a change in 
phosphorylation of AMPK at Thr
172
, we found that there was a slight increase when 
compared to the control, though at levels nowhere near that of the increase in Ser
485
 
(Figure 6D). To determine the effect on AMPK activity after PMA treatments we 
measured the phosphorylation of ACC at Ser
97
, the site directly phosphorylated by 
activated AMPK, and found that there is a significant (approximately 50%) decrease in 
phosphorylation at this site (Figure 6E). 
 
Increased AMPK phosphorylation at Ser
485 
after troglitazone incubation is not associated 
with changes in PKD1 in HepG2 cells. 
With the PPARγ-independent mechanism of troglitazone being uncertain, we 
sought to compare our current experiment with other known causes of AMPK Ser
485
 
phosphorylation and their mechanisms. In specific we looked at the PKC family of 
kinases, especially the newly elucidated PKD (Coughlan et al., 2016). Despite seeing an 
increase in AMPK Ser
485
 phosphorylation in HepG2 cells incubated with both PMA and 
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troglitazone individually, we found no significant increase in PKD phosphorylation in the 
troglitazone treated cells (Figure 6B). Despite both troglitazone and PMA increasing 
Ser
485
 phosphorylation almost 8-fold, there was no significant increase at this site when 
cells were phosphorylated by troglitazone follow by PMA (Figure 6B). There was a slight 
decrease in AMPK Thr
172
 phosphorylation when PMA was added to cells that had been 
incubated with troglitazone for 1 hour; however this decrease was not statistically 
significant (Figure 6D). It was observed that cells treated with troglitazone followed by 
PMA showed a significant increase in pACC Ser
79
 phosphorylation compared to cells 
treated with only PMA that showed a decrease in pACC Ser
79
 (Figure 6E). These results 
were especially significant due to the fact that both PMA alone and Troglitazone + PMA 
treatments increased AMPK phosphorylation at Thr
172
 and Ser
485
 in a similar manner 
(Figure 6). 
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Figure 6. HepG2 cells treated with troglitazone and PMA both increase 
AMPK phosphorylation at Ser
485
 and Thr
172
, although they have different effects on 
the phosphorylation of PKD and ACC. 
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HepG2 cells were treated with 50nM of PMA for 30 minutes (lane 2), 50μM of 
troglitazone for 1 hour (lane 3), or 50μM of troglitazone for 1 hour followed by 50nM of 
PMA for 30 minutes (lane 4). Western blot analysis was used to determine changes in p-
PKD Ser
916
, p-AMPK Ser
485
, p-AMPK Thr
172
, and p-ACC Ser
79
 (panel A). Panels B, C, 
D, and E are the quantification of the data obtained from panel A. Data are means ± 
SEM. N = 6 samples per group. *P < 0.05 compared to control group. 
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DISCUSSION 
 
 In order to find new and improved ways of treating T2D it is vital that we gain a 
more in-depth understanding of the effects that anti-diabetic treatments, such as TZDs, 
have on molecules implicated in the disease. In 2014, Coughlan et al. emphasized the 
importance of AMPK as a potential therapeutic target and, although the TZD troglitazone 
is known to activate AMPK in some tissues, the mechanisms that link this drug and target 
molecule are not yet fully understood. Although it has long been presumed that 
troglitazone’s effect on AMPK, if any, was directly a result of Thr172 phosphorylation, we 
have shown that in HepG2 cells at least, the reality is not as simple. 
 In this study we first sought to discover whether troglitazone treatments increase 
AMPK phosphorylation at Thr
172 
in HepG2 cells. We found that, not only does AMPK 
phosphorylation at this location increase significantly over time, the trending increase is 
seen as early as 5 minutes, and it says elevated for up to 12 hours incubation (Figures 3B 
and 4B). These data support the growing body of research describing the increased Thr
172
 
phosphorylation of AMPK after troglitazone treatment in other cell types. More 
specifically, our data also support the results of LeBrassur et al. that demonstrated an 
increase in AMPK activation by TZDs in a time period too rapid to account for the 
proposed PPARγ-dependent mechanism of action. In EDL muscle, AMPK activation was 
seen in as little as 5 minutes, the same time-period as was seen in our own study of 
HepG2 cells (LeBrasseur et al., 2006). 
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To support the hypothesis that increased phosphorylation at Thr
172
 of AMPK 
meant increased AMPK activation, we measured the phosphorylation of ACC at Ser
79
, a 
site directly phosphorylated by AMPK. We found that phosphorylation at this site 
increased in a time-dependent manner similar to the increase p-AMPK Thr
172
, with the 
earliest increase seen also at 5 minutes (Figure 3D). These data support the 
aforementioned research performed in other cells types, providing strong evidence 
troglitazone does increase AMPK activity in HepG2 cells. It is, however, important to 
note that, although ACC phosphorylation remained elevated through an extended time 
course, up to 6 hours, there was an observable decrease at by 12 hours suggesting (Figure 
4D). This suggests the possibility that other factors regarding AMPK regulation are 
involved over a longer time-scale and provides an area of potential further investigation 
into what these other factor may be. 
 The lesser known site of AMPK phosphorylation at Ser
485
 has more recently been 
implicated as a potential target for T2D treatment, and a large number of studies are 
showing that phosphorylation at this site can inhibit AMPK, regardless of whether the 
molecule is phosphorylated at Thr
172
 (Dagon et al., 2012) (Hawley et al., 2014). Due to 
the increasing emphasis on this site in the literature, we sought to discover whether 
troglitazone would have any effect at this site in HepG2 cells. To our knowledge, the 
effects of TZD treatment on p-AMPK Ser
485
 have not been examined prior to this study. 
We found that troglitazone does affect p-AMPK Ser
485
 and observed a marked increase in 
phosphorylation at this site for up to 2 hours of incubation, after which phosphorylation 
progressively decreased (Figure 4C). As with Thr
172
, an upward trend of p-AMPK Ser
485
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phosphorylation can be seen prior to one hour incubation beginning as early as 5 minutes, 
although the results were not statistically significant potentially a result of the relatively 
small sample size (Figure 3C). These results are interesting in a few different ways. To 
begin with, this is the first study, to our knowledge, that shows a concurrent increase in 
phosphorylation at the Thr
172
 and Ser
485
 sites on AMPK. As discussed previously, these 
two sites have been shown to be phosphorylated either in an opposing manner (with one 
increasing and the other decreasing) or in a manner when one is affected while the other 
is not. Our previous findings in EDL skeletal muscle demonstrated that the two sites are 
not directly related and can be phosphorylated or dephosphorylated over different time-
courses in response to high glucose (Coughlan et al., 2016). The results from this study 
provide even more insight into the potentially disparate mechanisms of phosphorylation, 
showing that phosphorylation at the two sites is neither time-relate, nor dependent on the 
level of phosphorylation at the other site. Interestingly, despite this increase at both sites, 
the net result was found to increase AMPK activation, a reasonable, assumption given 
that the increase in Thr
172
 phosphorylation was greater than or equal to that of Ser
485
 at 
almost every time point and dose amount measured (Figures 3, 4, and 5).  
 After determining that troglitazone treatment not only phosphorylates Thr
172
 but 
also Ser
485
 on AMPK, the next step was to consider the potential mechanism behind this 
phosphorylation. We decided to focus on our most recent research which found that PKD 
(a member of the PKC family of kinases) is a novel upstream kinase of Ser
485
 in C2C12 
skeletal muscle cells and mouse EDL muscle (Coughlan et al., 2016). In the previous 
experiment, PKD was activated by treatment with PMA, a mimetic of DAG (Coughlan et 
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al., 2016). This experiment was reproduced using HepG2 cells in order to determine 
whether this newly elucidated mechanism occurred in different yet similarly important 
cell types when considering the T2D disease process (see introduction). Our data support 
the results of the previous study, finding that a 30 minute incubation with 50nM of PMA 
did, as before, effectively increase levels of p-PKD Ser
916
 as well as levels of p-PKD 
Ser
485
 (Figure 6). This new evidence greatly supports the idea of PKD as a new AMPK 
kinase and highlights the need to discover the potentially vast mechanisms of AMPK 
regulation that are yet unknown. It should be noted here that, without specific PKD 
inhibitor experiments, it cannot be conclusively stated that the increase in p-AMPK Ser
485
 
is a direct result of the increase in p-PKD Ser
916
. Further experimentation using inhibitors 
is recommended to definitively support the previously mentioned claims. 
An unexpected result of this experiment was the increase in p-AMPK Thr
172
 after 
PMA treatment, a result not before seen in other cell types (Figure 6D). Although the 
increase was small compared to that of pAMPK Ser
485
, ~3 fold vs. ~7 fold (Figure 6), it is 
important to take note of this discovery, as our previous experiments found no significant 
change in Thr
172
 levels after PMA treatment (Coughlan et al., 2016). Despite this increase 
in Thr
172
 phosphorylation, phosphorylation of ACC at Ser
97
 was significantly decreased 
with PMA treatments (Figure 6). These data suggest that the overriding effect on AMPK 
activity was a result of the much greater amount of phosphorylation at Ser
485
, not at 
Thr
172
 (Figure 6). To further understand whether the phosphorylation at Thr172 has an 
impact on the function of the AMPK after PMA treatments it is recommended that 
AMPK activity level testing be performed on the samples from these experiments.  
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After finding evidence for PKD phosphorylation of AMPK at Ser
485
 in HepG2 
cells we then looked for any changes in PKD after troglitazone treatments. Despite the 
increase in p-AMPK Ser
485
, there was no significant change in p-PKD Ser
916
 levels after 
1 hour of 50μM troglitazone incubation when compared to the control, leading to the 
conclusion that an upstream kinase other than PKD is responsible for the p-AMPK Ser
485
 
increase (Figure 6). Despite this lack of correlation, there are a growing number of known 
upstream kinases that phosphorylate AMPK at Ser
485
 and any one of these, or a 
completely new kinase, could be responsible for the actions of troglitazone in HepG2 
cells. 
 
Future Research 
Further research into the identity of this still unknown kinase will be important in 
elucidating the PPARγ-independent effects of troglitazone on AMPK in HepG2 cells, as 
well as in understanding new mechanisms involving p-AMPK-Ser
485/491
. The next step in 
this research will be to test other known p-AMPK Ser
485
 kinases, starting with Akt, to 
determine what mechanism the troglitazone is activating to bring about these changes. 
Akt has been shown to phosphorylate Ser485 in conditions of high insulin, and is a 
promising novel mechanism when searching for the kinase activated by troglitazone 
treatments (Valentine et al., 2014). In addition to looking at Akt, a large-scale search of 
other PKCs may also provide new and valuable information regarding AMPK 
activation/inhibition in response to both disease states and drug treatments. As mentioned 
before, assays that directly measure AMPK activity ought to be performed in each of the 
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experiments described above. The results of these tests will give a more direct insight 
into what is happening to the AMPK molecule under conditions where Thr
172
 and Ser
485
 
are activated simultaneously. 
New mechanisms of AMPK Ser
485
 phosphorylation and their effects on the 
activity of AMPK are an exciting and important aspect in understanding the function of 
AMPK and its role in T2D and other metabolic diseases. Understanding the effects on 
AMPK of the other thiazolidinediones, rosiglitazone and pioglitazone, as well as other 
T2D drugs such as metformin, is also an important area of future research. The more we 
understand these currently used drugs’ mechanism of action and the further we are able to 
pinpoint the molecular basis of their positive and negative effects, the better we will 
become at making safer and more effective medications. 
 Lastly it should be noted that, although this research was conducted through the 
lens of type 2 diabetes research, AMPK has been shown to be an important molecule in 
many other disease processes, including cancer. The increasing evidence that AMPK is 
implicated in such a wide variety of disease processes opens the doors new ways of 
combatting diseases and will hopefully provide novel ideas for therapeutic interventions.  
 
Conclusion 
 In this study it was found that the TZD troglitazone activated AMPK via 
phosphorylation of Thr
172
 via a time- and dose- dependent manner in cultured 
hepatocytes. These data support the idea of a PPARγ-independent mechanism of TZD 
action that has been previously proposed in the literature. It was also shown that 
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troglitazone phosphorylated AMPK at its Ser
485
 inhibitory site, a novel discovery. To our 
knowledge, this is the first time we have seen AMPK increasingly phosphorylated at both 
Thr
172
 and Ser
485
. This leaves the door wide open for new research to delve further into 
the both the mechanisms of Ser
485
 phosphorylation and the effects this has on the AMPK 
molecule as a whole. Lastly, our data showed that PMA treatments increase AMPK 
Ser
485
 phosphorylation in HepG2 cells, supporting the results of the recent findings in 
skeletal muscle (Coughlan et al., 2016). Despite this, we concluded that the increase in 
PMA was not cause of the increase in AMPK Ser
485
 phosphorylation after troglitazone 
treatment, a mechanism which is yet to be discovered. 
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